We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Prognostic Value of Prothrombin Fragments 1+2 for Pulmonary Embolism Incidence

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01078792
Recruitment Status : Unknown
Verified March 2010 by Hillel Yaffe Medical Center.
Recruitment status was:  Not yet recruiting
First Posted : March 2, 2010
Last Update Posted : March 2, 2010
Information provided by:
Hillel Yaffe Medical Center

Brief Summary:
To determine the possible association of prothrombin fragments 1+2 elevation with incidents of pulmonary embolism in patients with COPD exacerbation.

Condition or disease Intervention/treatment
Pulmonary Disease, Chronic Obstructive Disease Exacerbation Pulmonary Embolism Prothrombin Fragments Other: CT pulmonary angio, blood tests

Study Type : Observational
Observational Model: Cohort
Time Perspective: Prospective

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Group/Cohort Intervention/treatment
COPD exacerbation
Patients admitted to hospital with COPD exacerbation
Other: CT pulmonary angio, blood tests

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients admitted to hospital due to COPD exacerbation

Inclusion Criteria:

  • COPD exacerbation
  • Able to give informed consent
  • Able to perform spirometry

Exclusion Criteria:

  • Known malignancy
  • Known hypercoagulable state
  • Receiving anticoagulant treatment
  • Pregnancy
  • Renal failure
  • Allergy to Iodine

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01078792

Hillel Yaffe Medical Center Not yet recruiting
Hadera, Israel, 38100
Contact: M Beckerman, MD       marinellab@hy.health.gov.il   
Principal Investigator: M Beckerman, MD         
Sponsors and Collaborators
Hillel Yaffe Medical Center

Responsible Party: Marinella Beckerman, Hillel Yaffe Medical Center
ClinicalTrials.gov Identifier: NCT01078792     History of Changes
Other Study ID Numbers: 0001-10
First Posted: March 2, 2010    Key Record Dates
Last Update Posted: March 2, 2010
Last Verified: March 2010

Additional relevant MeSH terms:
Lung Diseases
Pulmonary Embolism
Chronic Disease
Pulmonary Disease, Chronic Obstructive
Disease Progression
Respiratory Tract Diseases
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Disease Attributes
Pathologic Processes
Lung Diseases, Obstructive